real-time news and commentary for investors
Tuesday, Jul 24
2012, 5:38 PM
More on Qiagen (QGEN): Q2 earnings were nearly flat as the provider of medical-testing...
More on Qiagen (QGEN): Q2 earnings were nearly flat as the provider of medical-testing technologies revenue growth was masked by higher acquisition-related costs and other expenses. The company raises its FY12 EPS estimate to $1.04 - $1.06 on sales growth of 8% - 9%, versus its prior estimate of $1.03 - $1.05 on sales growth of 6% - 8%, and unveils a stock buyback of up to $100M.